L Ye1,2, T M Mauro3, E Dang4, G Wang4, L Z Hu5, C Yu4, S Jeong6, K Feingold3,7, P M Elias3, C Z Lv2, M Q Man1,3. 1. Dermatology Hospital, Southern Medical University, Guangzhou, China. 2. Dalian Skin Disease Hospital, Dalian, Liaoning, China. 3. Dermatology Service, Veterans Affairs Medical Center and Department of Dermatology, University of California San Francisco, San Francisco, CA, USA. 4. Department of Dermatology, Xijing Hospital, 4th Military Medical University, Xi'an, China. 5. Immunology Department, Key Laboratory of Immune Microenvironment and Disease (Ministry of State Education), Tianjin Medical University, Tianjin, China. 6. Department of Bio-Cosmetic Science, Seowon University, Cheongju, South Korea. 7. Metabolism Section, Veterans Affairs Medical Center, San Francisco, CA, USA.
Abstract
BACKGROUND: While increased levels of circulating inflammatory cytokines in chronologically aged humans have been linked to the development of ageing-associated chronic disorders (e.g., cardiovascular disease, type II diabetes, osteoporosis and Alzheimer's disease), approaches that reduce circulating cytokines are not yet available. In chronologically aged mice, we recently demonstrated that epidermal dysfunction largely accounts for age-associated elevations in circulating cytokine levels, and that improving epidermal function reduced circulating cytokine levels. OBJECTIVE: We performed a pilot study to determine whether improving epidermal function reduces circulating pro-inflammatory cytokine levels in aged humans. METHODS: Thirty-three aged humans were topically treated twice-daily for 30 days, with ≈ 3 mL of an emollient, previously shown to improve epidermal function, while untreated, aged humans and a cohort of young volunteers served as controls. Changes in epidermal function and levels of three key, age-related, plasma cytokines (IL-1β, IL-6 and TNFα) were measured at baseline and after treatment, using Luminex 200™ system. RESULTS: We also found significantly higher baseline levels of IL-1β, IL-6 and TNFα in aged vs. young humans (P < 0.001), as previously reported. Topical applications of the barrier repair emollient significantly enhanced epidermal permeability barrier function (P < 0.01) and stratum corneum hydration (P < 0.05). In parallel, circulating levels of IL-1β and IL-6 normalized, while TNFα levels declined substantially. CONCLUSION: The results of this preliminary study suggest that a larger clinical trial should be performed to confirm whether improving epidermal function also can reduce circulating pro-inflammatory cytokine levels in aged humans, while also possibly attenuating the downstream development of chronic inflammatory disorders in the aged humans.
BACKGROUND: While increased levels of circulating inflammatory cytokines in chronologically aged humans have been linked to the development of ageing-associated chronic disorders (e.g., cardiovascular disease, type II diabetes, osteoporosis and Alzheimer's disease), approaches that reduce circulating cytokines are not yet available. In chronologically aged mice, we recently demonstrated that epidermal dysfunction largely accounts for age-associated elevations in circulating cytokine levels, and that improving epidermal function reduced circulating cytokine levels. OBJECTIVE: We performed a pilot study to determine whether improving epidermal function reduces circulating pro-inflammatory cytokine levels in aged humans. METHODS: Thirty-three aged humans were topically treated twice-daily for 30 days, with ≈ 3 mL of an emollient, previously shown to improve epidermal function, while untreated, aged humans and a cohort of young volunteers served as controls. Changes in epidermal function and levels of three key, age-related, plasma cytokines (IL-1β, IL-6 and TNFα) were measured at baseline and after treatment, using Luminex 200™ system. RESULTS: We also found significantly higher baseline levels of IL-1β, IL-6 and TNFα in aged vs. young humans (P < 0.001), as previously reported. Topical applications of the barrier repair emollient significantly enhanced epidermal permeability barrier function (P < 0.01) and stratum corneum hydration (P < 0.05). In parallel, circulating levels of IL-1β and IL-6 normalized, while TNFα levels declined substantially. CONCLUSION: The results of this preliminary study suggest that a larger clinical trial should be performed to confirm whether improving epidermal function also can reduce circulating pro-inflammatory cytokine levels in aged humans, while also possibly attenuating the downstream development of chronic inflammatory disorders in the aged humans.
Authors: Eung-Ho Choi; Mao-Qiang Man; Pu Xu; Shujun Xin; Zhili Liu; Debra A Crumrine; Yan J Jiang; Joachim W Fluhr; Kenneth R Feingold; Peter M Elias; Theodora M Mauro Journal: J Invest Dermatol Date: 2007-06-07 Impact factor: 8.551
Authors: Si Wen; Jiechen Zhang; Bin Yang; Peter M Elias; Mao-Qiang Man Journal: Evid Based Complement Alternat Med Date: 2020-04-14 Impact factor: 2.629
Authors: Kyong-Oh Shin; Debra A Crumrine; Sungeun Kim; Yerin Lee; Bogyeong Kim; Katrina Abuabara; Chaehyeong Park; Yoshikazu Uchida; Joan S Wakefield; Jason M Meyer; Sekyoo Jeong; Byeong Deog Park; Kyungho Park; Peter M Elias Journal: BMC Neurosci Date: 2021-06-22 Impact factor: 3.288